ArticleCancer research communications2026
Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
Abstract
Proteins belonging to the Schlafen family are interferon-inducible and participate in the regulation of antiviral responses, immune signaling, and proteotoxic stress. Schlafen 11 (SLFN11) also kills cells with replicative damage, serving as a predictive biomarker for chemotherapeutic response. In this study, we examined SLFN11 expression and significance in multiple myeloma. The Cancer Genome Atlas and MMRF CoMMpass datasets were analyzed for SLFN11 expression. Bone marrow and cell lines samples were analyzed for SLFN11 protein. SLFN11-knockout multiple myeloma cell lines were used to explore how SLFN11 affects bortezomib (BTZ) response. Retrospective analysis of the HOVON-65/GMMG-HD4 phase III trial (n = 327) assessed clinical relevance. SLFN11 is consistently highly expressed across multiple myeloma subtypes (except CD1 and MAF/MAFB) and in normal plasma cells, and its expression strongly correlates with super-enhancer-driven plasma cell transcriptional programs. CD138-positive normal and myeloma plasma cells retain SLFN11 expression even when proliferative activity (MKI67/Ki-67) increases with disease progression. BTZ, a first-line multiple myeloma treatment, induces SLFN11 nucleolar translocation with suppression of ribosomal RNA (rRNA) synthesis. Knocking out SLFN11 in multiple myeloma cells enhances BTZ sensitivity and exatecan resistance, supporting SLFN11's protective role in proteotoxic stress and sensitizing role in replication stress. In the HOVON-65/GMMG-HD4 trial, SLFN11-low patients seemed to preferentially benefit from BTZ-based therapy, suggesting that SLFN11 expression may guide therapeutic stratification in multiple myeloma. SIGNIFICANCE: SLFN11 is highly expressed in normal and malignant plasma cells. BTZ induces SLFN11 nucleolar translocation, suppressing rRNA synthesis. SLFN11 confers BTZ resistance while sensitizing to topoisomerase I inhibitors. Low SLFN11 expression may identify patients more likely to benefit from BTZ-based therapy, providing a mechanistic rationale for SLFN11-guided therapeutic stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.